

CONTENTS

Chapter 1. General Introduction.....	1-7
1.Introduction.....	1
AIMS AND OBJECTIVES.....	5
Prologue.....	6
Chapter 2. Review of literature.....	8-42
Tuberculosis.....	8
2.1.1 The history of TB.....	8
2.1.2 The bacterium.....	14
2.1.3 Pathophysiology of tuberculosis.....	16
2.1.4 Immunity in tuberculosis.....	18
2.1.4.1 The innate Immunity.....	18
2.1.4.2 The Adaptive Immunity: Important role of cytokines.....	19
2.1.5 Treatment of TB.....	21
2.1.5.1 Emerging problem of Drug resistance.....	21
2.1.6 Human genetic susceptibility to infectious diseases.....	22
2.1.6.1 Evidences for genetic influence in governing susceptibility to tuberculosis:.....	23
2.1.7 Study designs and choice of marker.....	25
2.1.7.1 Choice of markers.....	26
2.1.7.1.1 Restriction fragment length polymorphisms (RFLPs).....	26
2.1.7.1.1.2 Microsatellites.....	27
2.1.7.1.3 Single nucleotide polymorphism (SNP): the great importance of small differences.....	27
2.1.7.2 Human genetic traits.....	28
2.1.7.2.1 Simple monogenic traits.....	28
2.1.7.2.2 Multi-factorial common complex traits.....	28
2.1.7.2.3 Study designs.....	29
2.1.7.2.3 .1 Linkage studies.....	29
2.1.7.2.3 .2 Association studies.....	31
2.1.7.2.3 .2 a) Population-based case-control studies for polymorphisms and candidate genes.....	33
2.1.7.2.3 .2 b) Family-based studies for polymorphisms and candidate genes.....	34
2.1.7.2.3 .2 c) Genome-wide association studies.....	35
2.1.8 Gene-gene interactions.....	36
2.1.9 Key concepts in statistical genetics.....	37
2.1.9.1 Hardy–Weinberg equilibrium.....	37
2.1.9.2 Haplotypes and Linkage disequilibrium.....	39
2.1.9.3 Type 1 and type 2 error rates and correction for multiple testing.....	41
2.1.9.4 Population stratification.....	41

2.1.10 Previous studies done on genetic susceptibility to tuberculosis	42
--	----

Chapter 3. Materials, methods and statistical analysis.....43-76

3.1 Study participants.....	43
3.1.1 Calculation of sample size required for the study.....	43
3.1.2 Ethical aspects.....	43
3.1.3 Participants selection	43
3.1.4 Study population and Stratification.....	45
3.2 DNA and serum samples.....	46
3.2.1 DNA extraction from blood and quality testing.....	46
3.2.2 Serum separation from blood.....	47
3.3 Gene and SNP selection for the study	47
3.3.1 Determining the genes to be studied for the current study	47
3.3.2 Selection of sequence variants in the genes chosen above	47
3.3.3 Further Criteria employed for selection of adaptive panel	48
3.3.4 Study Design.....	53
3.3.4.1 The innate immune gene panel	53
3.3.4.2 The Adaptive immunity gene panel	53
3.4 Methods of genotyping.....	54
3.4.1 Sequenom genotyping using iPLEX TM Gold chemistry	54
3.4.1.1 Primer designing.....	55
3.4.1.2 Template amplification.....	57
3.4.1.3 Dephosphorylation.....	58
3.4.1.4 Homogenous MassEXTEND (hME) reaction	59
3.4.1.5 Sample conditioning and transfer	59
3.4.2 Genotyping using Tetra – primer Amplification refractory mutation system Polymerase Chain Reaction (ARMS-PCR).....	60
3.4.2.1 Tetra- primer ARMS-PCR protocol.....	61
3.4.2.2 Gel electrophoresis for ARMS-PCR products.....	66
3.4.2.3 Sequencing of the ARMS-PCR products.....	67
3.5 Enzyme –linked Immunosorbent assay for serum cytokine assessment.....	67
3.6 Genetic and Statistical Analysis	67
3.6.1 Quality Checking of the genotype data.....	67
3.6.2 Analysis of population stratification (PS).....	68
3.6.3 Allelic and genotypic association test.....	74
3.6.4 The chi-square test	74
3.6.5 The Fisher’s exact test.....	75

3.6.6 Haplotypes and Linkage disequilibrium	75
3.6.7 Statistical analysis of serum cytokine levels.....	75
Chapter 4. Genetic variants in the innate immunity genes and there effect on susceptibility to tuberculosis (PTB and ETB) in north Indians.....	77-133
4.0 Introduction.....	77
4.1 P_2X_7/P_2RX_7 gene and tuberculosis susceptibility	78
4.1.1 Results.....	79
4.1.1.1 P_2X_7 variants and susceptibility to pulmonary tuberculosis.....	80
4.1.1.2 P_2X_7 variants and susceptibility to lymph node tuberculosis	80
4.1.1.3 The P_2X_7 variants and tuberculosis susceptibility	80
4.2 <i>VDR</i> gene polymorphism and susceptibility to tuberculosis	83
4.2.1 Results.....	83
4.2.1.1 <i>VDR</i> polymorphisms and susceptibility to pulmonary tuberculosis.....	84
4.2.1.2 <i>VDR</i> polymorphisms and susceptibility to lymph node tuberculosis	84
4.2.3 Discussion	85
4.3 <i>DC-SIGN</i> encoded by <i>CD209</i> gene polymorphism and susceptibility to tuberculosis	91
4.3.1 Results.....	92
4.3.1.1 <i>DC-SIGN (CD209)</i> gene variant and susceptibility to pulmonary tuberculosis.....	93
4.3.1.2 <i>DC-SIGN (CD209)</i> gene variant and susceptibility to lymph node tuberculosis	93
4.3.2 Discussion	93
4.4 <i>IRGM</i> gene polymorphism and susceptibility to tuberculosis	94
4.4.1 Results.....	96
4.4.1.2 <i>IRGM</i> variant and susceptibility to pulmonary tuberculosis.....	96
4.4.1.3 <i>IRGM</i> variant and susceptibility to lymph node tuberculosis.....	97
4.4.3 Discussion	97
4.5 <i>SLC11A1</i> gene (formerly <i>NRAMP1</i>) polymorphism and susceptibility to tuberculosis	99
4.5.1 Results.....	100
4.5.1.1 <i>NRAMP1</i> gene polymorphisms and susceptibility to tuberculosis	100
4.5.2 Discussion	101
4.6 Toll-like receptor (2, 4 and 8) polymorphisms and tuberculosis	102
4.6.1 Results.....	104
4.6.1.1 <i>TLR2</i> polymorphism and susceptibility to tuberculosis.....	105
4.6.1.2 <i>TLR4</i> polymorphism and susceptibility to tuberculosis.....	105
4.6.1.3 <i>TLR8</i> polymorphisms and tuberculosis.....	105
4.6.1.3.1 Allelic association <i>TLR8</i> polymorphisms and PTB	106
4.6.1.3.2 Allelic association <i>TLR8</i> polymorphisms and LNTB	107
4.6.2 Discussion	107
4.7 <i>SP110</i> polymorphism and susceptibility to tuberculosis.....	110
4.7.1 Results.....	112

4.7.1.1	<i>SP110</i> variants and susceptibility to pulmonary tuberculosis.....	112
4.7.1.2	<i>SP110</i> variants and susceptibility to lymph node tuberculosis	112
4.7.2	Discussion	113
4.8	<i>IL17</i> genetic polymorphism and susceptibility to tuberculosis.....	116
4.8.1	Results.....	118
4.8.1.1	Mean serum IL-17A and IL-17 F levels :	118
4.8.1.2	<i>IL17A</i> variants and susceptibility to pulmonary and lymph node tuberculosis	118
4.8.1.3	<i>IL17A</i> gene polymorphism and serum IL-17A levels	119
4.8.1.4	<i>IL17F</i> gene polymorphism and serum IL-17F levels	119
4.8.2	Discussion	120
4.9	<i>LTA4H</i> genetic polymorphism and tuberculosis susceptibility.....	123
4.9.1	Results.....	124
4.9.1.1	Allelic association of <i>LTA4H</i> polymorphism with PTB and LNTB	124
4.9.1.2	Haplotypes association of <i>LTA4H</i> polymorphism with PTB and LNTB.....	125
4.9.1.3	Association of <i>LTA4H</i> polymorphism using the heterozygosity model.....	126
4.9.1.4	Discussion	126
4.10	<i>NOS2A</i> polymorphism and tuberculosis susceptibility.....	129
4.10.1	Results.....	130
4.10.1.1	Allelic association of <i>NOS2A</i> polymorphisms and tuberculosis.....	130
4.10.2	Discussion	131
Chapter 5. Cytokine gene variants and their effect on susceptibility to tuberculosis (PTB and EPTB) in north Indians.....		134- 158
5.1.a.	Introduction	134
5.1. b	Association studies on cytokine gene polymorphism and tuberculosis.....	136
5.1. b.1	Interferon- γ and its receptors	136
5.1. b.2	Interleukin -12 (IL-12) and receptors	137
5.1. b. 3	Interleukin (IL) -1	137
5.1. b. 4	Interleukin (IL)-2	138
5.1. b. 5	Interleukin (IL)-4	138
5.1. b. 6	Interleukin (IL) - 6	138
5.1. b. 7	Interleukin (IL) -10	139
5.1. b. 8	Tumor necrosis factor-a	139
5.1. b. 9	Chemokine and receptors.....	140
5.1. b. 10	Interleukin (IL) -8	140
5.2	Results.....	143
5.2.1	Cytokine genetic variants Results of Phase I a.	145
5.2.1.1	Allelic and haplotypic association of Cytokine gene variants in combined TB group (PTB+LNTB).....	145
5.2.1.2	Allelic and haplotypic association of cytokine gene variants in PTB.....	147
5.2.1.3	Allelic and haplotypic association of cytokine gene variants in LNTB.....	149

5.2.1.4 Interpretation.....	150
5.2.2 Cytokine genetic variants Results of Phase I b.....	151
5.2.2.1 Allelic associations of cytokine SNPs and the risk of pulmonary tuberculosis.....	151
5.2.2.1.1 <i>IFNG</i> polymorphism and PTB susceptibility.....	151
5.2.2.1.2 <i>IL4</i> polymorphism and PTB susceptibility.....	152
5.2.2.1.3 <i>IL1RA</i> polymorphism and PTB susceptibility.....	152
5.2.2.1.4 <i>IL12</i> polymorphism and PTB susceptibility.....	153
5.2.2.1.5 <i>IL1B</i> polymorphism and PTB susceptibility.....	153
5.2.2.1.6 <i>TNFB</i> polymorphism and PTB susceptibility.....	153
5.2.2.2 Interpretation.....	153
5.2.3 Analysis for the selected variants in Phase II analysis.....	156
5.3 Discussion.....	157

Chapter 6. Estimation of the spectrum of serum cytokine response in PTB and LNTB

in north Indians..... 159-173

6.1 Cytokine research in tuberculosis: the current scenario.....	159
6.2 Results.....	160
6.2.1 Serum cytokines in pulmonary and lymph node TB in north Indians.....	161
6.2.2 Receiver operator curve analysis for sensitivity and specificity for both pulmonary and lymph node TB cases.....	162
6.2.3 Follow-up of the lymph node TB cases for checking the efficacy of the biomarker:.....	164
6.3. Discussion.....	165
6.3.1 The cytokine profile in PTB cases.....	165
6.3.2 Signature serum cytokines in LNTB: role as biomarkers and diagnosis.....	170

Chapter 7. Correlation of cytokine gene variants and mean serum cytokine levels in PTB and LNTB in north Indians.....174-188

7. Introduction.....	174
7.1 Results.....	176
7.1.1 Correlation between serum cytokine levels and pulmonary tuberculosis.....	176
7.1.1.1 <i>IFNG</i> polymorphisms and serum IFN- γ levels.....	176
7.1.1.2. <i>TNFA</i> polymorphisms and serum TNF- α levels.....	176
7.1.1.3 <i>IL4</i> gene polymorphism and serum IL-4 levels.....	177
7.1.1.4 <i>IL10</i> gene polymorphisms and serum IL-10 levels.....	177
7.1.1. 5 <i>IL12</i> gene polymorphisms and serum IL -12 levels.....	178
7.1.1.6 <i>IL8</i> gene polymorphisms and serum IL-8 levels.....	180
7.1.1.7 <i>IL6</i> gene polymorphisms and serum IL-6 levels.....	180
7.1.1.8 <i>IL18</i> gene polymorphisms and serum IL-18 levels.....	180
7.1.1.9 <i>IL1RA</i> gene polymorphisms and serum IL-1Ra levels.....	181

7.1.1.10 <i>IL1B</i> gene polymorphisms and serum IL-1 β levels	181
7.1.1.11 <i>TNFB</i> gene polymorphisms and serum TNF- β levels.....	181
7.1.1.12 <i>IL2</i> gene polymorphisms and serum IL-2 levels.....	182
7.1.2 Correlation between serum cytokine levels and lymph node tuberculosis	182
7.1.2.1 <i>IFNG</i> polymorphisms and serum IFN- γ levels.....	182
7.1.2.2. <i>TNFA</i> polymorphisms and serum TNF- α levels.....	182
7.1.2.3 <i>IL4</i> gene polymorphism and serum IL-4 levels	182
7.1.2.4 <i>IL10</i> gene polymorphisms and serum IL-10 levels.....	182
7.1.2. 5 <i>IL12</i> gene polymorphisms and serum IL -12 levels.....	183
7.1.2.6 <i>IL18</i> gene polymorphisms and serum IL-18 levels.....	183
7.1.2.7 <i>IL6</i> gene polymorphisms and serum IL-6 levels.....	184
7.1.2.8 <i>IL8</i> gene polymorphisms and serum IL-8 levels.....	184
7.1.2.9 <i>IL1RA</i> gene polymorphisms and serum IL-1Ra levels	184
7.1.2.10 <i>IL1B</i> gene polymorphisms and serum IL-1 β levels	184
7.1.2.11 <i>TNFB</i> gene polymorphisms and serum TNF- β levels.....	184
7.1.2.12 <i>IL2</i> gene polymorphisms and serum IL-2 levels.....	185
7.2 Discussion	185

Chapter 8. Interaction of the cytokine gene variants (gene-gene interaction): Influence on susceptibility to TB.....	189-194
8. Introduction.....	189
8.1 Results.....	190
8.3Discussion.....	191
Summary and conclusions.....	..195
Epilouge.....	198
References.....	199-215

Appendix

Publications